Edition:
United Kingdom

Arrowhead Pharmaceuticals Inc (ARWR.OQ)

ARWR.OQ on NASDAQ Stock Exchange Global Select Market

14.52USD
18 Jan 2019
Change (% chg)

$-0.11 (-0.75%)
Prev Close
$14.63
Open
$14.62
Day's High
$14.91
Day's Low
$14.10
Volume
647,359
Avg. Vol
673,290
52-wk High
$22.38
52-wk Low
$4.78

Chart for

About

Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce knockdown of... (more)

Overall

Beta: 1.91
Market Cap(Mil.): $317.78
Shares Outstanding(Mil.): 74.77
Dividend: --
Yield (%): --

Financials

  ARWR.OQ Industry Sector
P/E (TTM): -- 69.71 33.71
EPS (TTM): -0.67 -- --
ROI: -55.08 8.99 14.48
ROE: -61.13 10.13 15.99

J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion

Arrowhead Pharmaceuticals Inc said on Thursday Johnson & Johnson would develop and market its gene-silencing Hepatitis B treatment and buy a minor stake in a deal that could be potentially worth more than $3.7 billion (2.8 billion pounds), sending its shares surging 20 percent.

04 Oct 2018

J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion

Arrowhead Pharmaceuticals Inc said on Thursday Johnson & Johnson would develop and market its gene-silencing Hepatitis B treatment and buy a minor stake in a deal that could be potentially worth more than $3.7 billion, sending its shares surging 20 percent.

04 Oct 2018

UPDATE 1-J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 bln

* Shares gain as much as 20 pct premarket (Adds share movement and comment from analyst, CEO)

04 Oct 2018

J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 bln

Oct 4 Arrowhead Pharmaceuticals Inc said on Thursday Johnson & Johnson would develop and market its gene-silencing Hepatitis B drug and pick up a minor stake in the company in a deal that could be potentially worth more than $3.7 billion.

04 Oct 2018

Earnings vs. Estimates